RTW INVESTMENTS, LP: SPYRE THERAPEUTICS INC (SYRE): Quarterly 13F Position History
As of Q2 2026, RTW INVESTMENTS, LP reported 4,251,996 shares of SPYRE THERAPEUTICS INC (SYRE), worth $377.5M and representing 3.2% of its 13F equity book. Quarter-over-quarter share count change: + 80,000 (+1.9%) . The position first appeared in Q4 2023 and has been disclosed across 11 13F-HR filings in Pactolio's tracked window.
- 4,251,996Shares Held (Latest Filing)
- $377.5MReported Market Value (Latest Filing)
- 3.2%Portfolio Weight (% of 13F Equity Book)
- +80,000Quarter-over-Quarter Share Change
- +$167.1MQuarter-over-Quarter Value Change
- 4,251,996Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 11 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 4,251,996 | +80,000 | +1.9% | $377.5M | 3.2% | $88.8 |
| Q1 2026 | 4,171,996 | 0 | – | $210.4M | 2.1% | $50.4 |
| Q4 2025 | 4,171,996 | +550,000 | +15.2% | $136.7M | 1.4% | $32.8 |
| Q3 2025 | 3,621,996 | 0 | – | $60.7M | 0.7% | $16.8 |
| Q2 2025 | 3,621,996 | 0 | – | $54.2M | 0.8% | $15.0 |
| Q1 2025 | 3,621,996 | 0 | – | $58.4M | 0.9% | $16.1 |
| Q4 2024 | 3,621,996 | +363,636 | +11.2% | $84.3M | 1.3% | $23.3 |
| Q3 2024 | 3,258,360 | 0 | – | $95.8M | 1.4% | $29.4 |
| Q2 2024 | 3,258,360 | +1,025,600 | +45.9% | $76.6M | 1.2% | $23.5 |
| Q1 2024 | 2,232,760 | 0 | – | $84.7M | 1.3% | $37.9 |
| Q4 2023 | 2,232,760 | – | – | $48.0M | 0.8% | $21.5 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did RTW INVESTMENTS, LP first disclose a SYRE position in 13F-HR filings?
RTW INVESTMENTS, LP first reported SPYRE THERAPEUTICS INC (SYRE) on its 13F-HR filing for the period ending 2023-12-31 (Q4 2023). The position has appeared on 11 reported quarters within Pactolio's tracked window.
What was RTW INVESTMENTS, LP's most recent quarter-over-quarter share-count change in SYRE?
Between Q1 2026 and Q2 2026, RTW INVESTMENTS, LP added 80,000 shares of SYRE (+1.9%), bringing the total reported position to 4,251,996 shares at a market value of $377.5M.
Does the implied price-per-share represent RTW INVESTMENTS, LP's cost basis in SYRE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.